Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. - Klonoff DC; Buse JB; Nielsen LL; Guan X; Bowlus CL; Holcombe JH; Wintle ME; Maggs DG; Klonoff, David C; Buse, John B; Nielsen, Loretta L; Guan, Xuesong; et al. (Current Medical Research & Opinion, 2008)